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Abstract 
We measured the effects of individual modulators and of pairs of modulators of the multidrug resistance pump, P-glycoprotein, on the 
accumulation of labelled daunomycin to multidrug-resistant P388 leukemia cells at 37°C and developed a kinetic analysis which enables 
such data to be modelled in terms of co-operative, competitive or non-competitive interaction between pairs of modulators. The 
modulators verapamil, cyclosporin and trifluoperazine interacted with P-glycoprotein as single molecules, while vinblastine, mefloquine, 
dipyridamole, tamoxifen and quinidine displayed Hill numbers close to 2, suggesting that pairs of modulator molecules need to act 
together in order to bring about effective reversal of P-glycoprotein. When the modulators were presented to P-glycoprotein pairs, we 
found examples of both competitive and non-competitive b haviour. We interpret hese results on a model in which two modulatory sites 
exit on the MDR pump. To one of these, mefloquine, vinblastine and tamoxifen bind preferentially; to the other, verapamil, dipyridamole, 
trifluoperazine and quinidine bind (but mefloquine and tamoxifen only weakly if at all). Cyclosporin A can interact with both sites. 
Keywords: P-glycoprotein; Modulator interaction; Cooperativity; Interaction. competitive; Interaction, non-competitive; Multidrug resistance 
1. Introduction 
Resistance to the cytotoxic action of cancer chemo-ther- 
apeutic drugs is often associated with the manifestation of 
the multidrug, resistance (MDR) pump, P-glycoprotein, 
both in cells in culture and in patients [1-6]. P-Glyco- 
protein is a well-characterised membrane-bound protein, 
with demonstrable action as an ATPase [7-10]. Its activity 
results in a marked reduction in the intracellular concentra- 
tion of a wide range of compounds, these being the 
substrates of P-glycoprotein. Overcoming the action of this 
pump in a clinically acceptable fashion would be an 
important addition to our weapons against cancer. The 
action of P-glycoprotein in reducing intracellular drug 
concentrations can be reversed by a large range of com- 
pounds, many of them being well-studied pharmaceuticals 
in clinical use for conditions other than cancer [11 ]. Some 
of these, such as verapamil [12], quinidine [13], and cy- 
closporin A [14], have already been used in Phase I and 
Phase II clinical trials, in attempts to reverse drug resis- 
tance, but the high plasma levels of reversers that are 
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needed have limited the usefulness of this approach. We 
have been developing an approach in which combinations 
of many known modulators can be used in an attempt o 
use the low specificity of P-glycoprotein to block it 
(Lyubimov et al., unpublished results). 
For this approach to be successful, we need to under- 
stand the kinds of interactions that might occur between 
different modulators, which might allow one to use lower 
concentrations of each modulator in clinical modulations 
of drug resistance. Hu et al. [15], described a synergistic 
interaction between two modulators, cyclosporin A and 
verapamil, in multidrug resistant cells. In this paper we 
show, in a full experimental nd kinetic analysis, that both 
competitive (i.e., additive) and non-competitive (i.e., po- 
tentially synergistic) interactions [16], as well as co-oper- 
ative interactions [16], can take place between pairs of 
modulators in multidrug resistant P388 cells. 
2. Materials and methods 
2.1. Cell culture and treatment 
The cells used were a drug-resistant strain of P388 
leukemia cells, P388/ADR,  a kind gift from Prof. Avner 
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Ramu of the Hadassah-Hebrew University Hospital [17- 
19], as well as a strain of P388 cells that have been 
transfected with the human MDR1 gene, the VMDR C.04 
strain, this being a kind gift of Dr. M.M. Gottesman of the 
National Cancer Institute, Bethesda, MD. Both cell strains 
were grown in RPMI 1640 medium (Biological Industries, 
Kibbutz Beit Ha'emek, Israel) to which were added peni- 
cillin (100 units/ml), streptomycin (100 tzg/ml), ampho- 
tericin (0.25 /zg/ml), 10 /zM /3-mercaptoethanol, and 
0.2% (w/v)  glucose, together with 10% foetal calf serum 
(Biological Industries, Kibbutz Beit Ha'emek, Israel), the 
whole being hereafter termed complete RPMI medium, in 
5% CO2/humidified air at 37°C, in suspension culture, in 
260 ml plastic bottles (Nunc, Denmark). Before an experi- 
ment, cells were counted in an Analys Instrument (Sweden) 
model 134 cell counter, and the cells resuspended in fresh 
medium at 1.5 million cells per 1 ml medium for the 
subsequent transport assay. The cells were then held at 
least 1 h at 37°C to regenerate their full ability to pump 
substrate. (We, and others [20,21], have found that the 
degree of resistance xhibited by a multidrug resistant cell 
culture is somewhat dependent on the conditions under 
which they are cultured. To standardise our experimental 
conditions, we introduced this extra inhibition period in 
full, glucose-containing medium, just before a transport 
experiment is performed). Then, 1.0 ml of a suspension of 
cells in complete RPMI were transferred to a microfuge 
tube, and 30 pJ of the working solution of 3H-labelled 
cytotoxin (with sufficient cytotoxin to give a final concen- 
tration of daunomycin at 2 nM) containing the required 
concentration f reverser was added at zero time. Prelimi- 
nary experiments showed that the most reproducible re- 
sults were obtained at 60 m incubation at 37°C, for dauno- 
mycin. Uptake of the cytotoxin was stopped by rapid 
centrifugation i  the Beckmann model 11 microfuge at 
maximum speed for 1 min. The supernatant layer was 
immediately quantitatively removed by aspiration and the 
cell pellet resuspended in 0.4 ml 10% Triton X-100. The 
cell suspension was then transferred to vials for liquid 
scintillation counting, using Quiksafe A flurophor (Zinser 
Analytic, UK), in a Beckman (USA) 4S 600TA liquid 
scintillation counter. In all cases, aliquots of cells were 
incubated for comparable times with no reverser present, 
and zero time uptakes performed by adding appropriate 
aliquots of pre-cooled labelled daunomycin solutions to 
pre-cooled cell suspensions. The latter determination served 
to measure the amount of label trapped between the cells 
during centrifugation. It was generally some 5 to 10% of 
the maximum amount of label that was taken up during 60 
m in the presence of reverser. This was considered to be a 
sufficiently small factor to be neglected, since additional 
washing steps would have introduced indeterminate c ll 
losses. Known volumes of aliquots of the loading solutions 
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Fig. 1. Effect of two modulators of the P-glycoprotein on accumulation of daunomycin at 2 nM by P388 leukemia cells, incubated for 1 h at 37°C. (A) 
Verapamil, (B) vinblastine. The solid line in each figure is the best-fit curve fit to the accumulation equation (Eq. A-4) of Appendix A with a Hill number 
of 1, the dashed line with a Hill number of 2. For (A), each point is the mean (+ S.E.) of three separate xperiments each done in duplicate. For (B) each 
point is the mean (+ spread) of two experiments, each done in triplicate. 
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of cytotoxin) were taken for scintillation counting to en- 
able the conversion of the data from dpm per sample to 
fmoles of cytotoxin accumulated per million cells, in which 
units the data are reported. The amount of cytotoxin that is 
accumulated represents the sum of free intracellular cyto- 
toxin together with that bound intracellularly. No attempt 
was made to separate these two components, nor did any 
aspect of our data analysis depend on this separation being 
possible (see comment after Eq. A-4 of Appendix A). The 
cell suspension we used was sufficiently dilute that only 
negligible amounts of the cytotoxin were taken up by the 
time that the steady-state had been reached. The actual 
figure, as measured in a representative experiment was 
16% of the total cytotoxin in cells for which P-glyco- 
protein was blocked by maximal verapamil and 3% in the 
absence of this reverser. Thus, 84% and 97% of the total 
cytotoxin were still external to the cell at the steady-state, 
a difference which we felt we could ignore. 
2.2. Data analysis 
To obtain the appropriate values of the Michaelis pa- 
rameter, K i, for the effectiveness of a chemosensitiser on
counteracting the effect of P-glycoprotein on the accumu- 
lation of daunomycin, we used Eq. A-4 of Appendix A and 
the parallel Eq. A-7 and Eq. A-8. These give the depen- 
dence of the intracellular concentration of cytotoxin, Di, at 
any concentration C of one chemosensitiser, on the value 
of K~ for that chemosensitiser and the concentration of the 
second chemosensitiser, B, in terms of the accumulation i
the absence of reverser, D 0, and at infinitely high concen- 
Table 1 
MDR pump modulators: tests of significance of Hill number 2 and their 
kinetic characterisation 
Compound # data Ratio of Significance: Kint r ins i  c 
points variances n not = 2 (/zM) 
Cyclosporin 30 0.85 NS 0.035 
Dipyridamole 30 3.15 < 0.05 1.23 
Mefloquine 20 4.49 < 0.05 0.40 
Quinidine 18 8.62 < 0.05 0.56 
Tamoxifen 26 3.94 < 0.05 1.17 
Trifluoperazine 16 0.61 NS 0.89 
18 0.93 NS 0.81 
Verapamil 24 0.09 NS 0.23 
Vinblastine 28 3.82 < 0.05 0.87 
trations of reverser, D~. By fitting Eq. A-3 to the data of 
D i against C, at any value of B, using standard curve-fit- 
ting procedures, the appropriate values of Ki, Do, and D~ 
can be found. From the dependence of this computed value 
of K~ on the concentration of the second inhibitor, one can 
test whether the interaction between the two reversers is 
competitive or non-competitive and, in the former case, 
find the appropriate value of K~ for the second reverser. 
3. Results 
3.1. Studies using single reuersers 
Fig. 1 shows, on a semi-logarithmic scale, how the 
extent of daunomycin accumulation i  our drug-resistant 
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Fig. 2. Theoretical plots for the effect of pairs of modulators on the accumulation of a cytotoxin in drug-resistant cells, In (A), the two modulators interact 
competitively, in (B) non-competitively. The concentration f the variable modulator in (A) and (B) ranges from 0 to 10 X its Kins t r ins ic  while that of the 
fixed modulator is set at 0, 0.5, 1 or 1.5 X the value of its Kint r ins i  c .  In each plot, the inset is a plot of the value of Kint r ins i  c of the variable modulator at 
each of the four concentrations of the fixed modulator, as derived by curve-fitting of Eq. A-4 of Appendix A to the theoretical curves of the main figures. 
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P388/ADR cells is increased by increasing concentrations 
of the classical modulator verapamil (Fig. 1A) or by the 
addition of the multidrug pump's substrate vinblastine 
(Fig. IB). The solid line in both Fig. 1A and Fig. IB is the 
prediction of Eq. A-3 of Appendix A, that is, the case 
where the pump binds to, and is blocked by, single 
molecules of the reverser. The dashed line is for the case 
where 2 molecules of the reverser are needed to provide 
effective blocking of the pump, i.e., for a Hill number of 2. 
Clearly, single molecules of verapamil, but pairs of vin- 
blastine molecules, are needed to block P-glycoprotein. 
We applied a statistical analysis to these curve-fits. Our 
curve-fitting program gives us the variance remaining be- 
tween the data and the best curve fit, i.e., the sum of the 
squares of the deviations between the data points and the 
curve-fit. We calculate the ratio between the variances left 
after curve fitting using a Hill number of 1 to that left 
using a Hill number of 2 (or n). Entering Table A 14 of 
Snedecor and Cochran [22] for the distribution of the 
statistical parameter F enables us to reject one or other of 
these models. For verapamil (Fig. 1A), there is no reason 
to prefer the model with Hill number of 2, but for vinblas- 
tine (Fig. IB), the model with Hill number of 2 is prefer- 
able with a significance of P < 0.05. If the Hill number n 
was introduced as a free parameter, the best-fit value was 
found to be 1.81 _ 0.13, but the decrease in the variance 
obtained by using this value for n in place of 2 was not 
significant. For verapamil, the best-fit value of n was 
0.96 _+ 0.14 and there was no statistically significant de- 
crease in the variance when this number ather than 1 was 
chosen. Table 1 lists the ratio of variances found on 
curve-fitting these and several other reversers of P-glyco- 
protein. For verapamil, cyclosporin and trifluoperazine, a 
Hill number of 1 was appropriate out for dipyridamole, 
mefloquine, quinidine as well as vinblastine, a Hill number 
of 2 significantly improved the curve-fits. It would appear 
that at least pairs of these reverser molecules are needed to 
provide effective blocking of the pump's action. 
3.2. Comparison of m'o multidrug resistant P388 cell lines 
We wanted to verify that the results with the P388/ADR 
cell line were representative of other MDR lines. There- 
fore, we performed accumulation experiments uch as 
those depicted in Fig. 1 with a number of different re- 
versers of P-glycoprotein, using both the P388/ADR cells 
used in Fig. 1 and cells from a second multidrug resistant 
strain, the P388 VMDR C.04 cells, transfected with the 
human MDR1 gene. Table 2 records the values of the 
Michaelis parameter, Kt,tr, obtained using Eq. A-4 of 
Appendix A, found for 8 different reversers for these two 
strains of multidrug resistant P388 cells (P33/ADR and 
P388 VMDR C.04). The good accord between the two 
data sets suggests that the multidrug resistance for both 
cell strains arises from the presence of P-glycoprotein. 
3.3. Studies using re~,ersers in pairs 
Fig. 2A and B depict, respectively, the theoretical pre- 
dictions of Eq. A-7 and Eq. A-8 of Appendix A for the 
cases of competitive and non-competitive interactions be- 
tween pairs of reversers. In each case the concentration of 
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Fig. 3. Effect of mefloquine on accumulation f daunomycin at 2 nM by P388 leukemia cells, both in the presence and absence of cyclosporin A. (A): cells 
were incubated for 1 h at 37°C with a series of mefloquine concentrations (0, 0.2, 0.4, 0.8, 1.6, 3.2, 6.4, 12.8 ~M), containing different concentrations f 
cyclosporin: O, 0; v, 0.025; v, 0.05; D, 0.1 p.M. (B): the calculated values of Kintrinsi c (see text) for mefloquine ±S.E. are plotted against relevant 
cyclosporin A concentrations. 
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Table 2 
Values of the parameter gintrinsi c determined for two strains of multidrug 
resistant cells, P388/ADR and P388/VMDR C.04 
Reverser K i P388/ADR P388 VMDR C.04 
cells * cells * * 
Amiodarone 0.67 p,M 0.88 /xM 
Cyclosporin A 33.6 nM 38 nM 
Dipyridamole 1.15 p,M 0.52 /.zM 
Mefloquine 1.1 p,M 0.43 p,M 
Quinidine 0.35 p.M 0.29/zM 
Propaphenone 0.42 /xM 0.44/xM 
Tamoxifen 4.0/xM 1.4 p,M 
Verapamil 0.48 /xM 0.69 p~M 
(See Section 2, and Appendix A for Kintrinsic). 
" Data for P388/ADR cells are taken from Lan et al., in press. 
* * Data for P388 VMDR C.04 cells determined in this study as in Fig. 
1. 
one reverser (the variable reverser) is varied continuously 
while that of the other (the fixed reverser) is set at one of 
four fixed values. The four curves in each figure represent 
the increase in daunomycin accumulation brought about by 
increasing the variable substrate in the range 0 to 10 X its 
Km,  while the fixed substrate is set at 0, 0.5, 1, or 1.5 X its 
K m. From each curve we obtain, by curve-fitting to Eq. 
A-3 of Appendix A, the appropriate value of the intrinsic 
K r These are plotted in the inset of each figure. For 
competitive interactions, the value of K i increases linearly 
with the concentration of fixed reverser, while for non- 
competitive interactions it remains constant. 
How well do the experimental data obey these predic- 
tions? Fig. 3A shows the effect of increasing mefloquine 
concentrations on the accumulation of daunomycin at 2 
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Fig. 4. Competitive and non-competitive interactions between modulators of P-glycoprotein. Daunomycin accumulations at 2 nM by P388 leukemia cells, 
both in the presence and absence of verapamil (A,B,C) or trifluoperazine (D), the cells being incubated for 1 h at 37°C. (A-C): effect of cyclosporin A (A) 
or mefloquine (B). (A): a series of cyclosporin A concentrations (0, 0.0125, 0.025, 0.05, 0.1, 0.2, 0.4, 0.8 /xM) containing different concentrations of 
verapamil: O, 0; v ,  0.5; v ,  1.0; O, 2.0 /xM. (B): a series of mefloquine concentrations (0, 0.2, 0.4, 0.8, 1.6, 3.2, 6.4, 12.8 /zM), containing different 
concentrations of verapamih O, 0.0; v ,  0.5; v ,  1.0; O, 2.0 /.aM. (C): calculated values of Kintrinsi c (see text) for both cyclosporin A (open circles) and 
mefloquine (solid circles) -4-S.E., obtained from the curve-fit, plotted against relevant verapamil concentrations. (D): replots of similar experiments o
those depicted in (A) and (B), but with cyclosporin as the variable modulator (open circles) or mefloquine (solid circles), and trifluoperazine as the fixed 
modulator. Data are means -[- S.E. of three experiments (each of the type depicted in (A) and (B)) for cyclosporin and four for mefloquine. 
Table 3 
Characterising the interaction between pairs of MDR modulators 
Fixed Variable Type of K m 
modulator modulator interaction (/zM) 
Cyclosporin Mefloquine C 0.028 _+ 0.07 
Dipyridamole Verapamil C 1.8 _+ 0.5 
Mefloquine Verapamil NC * 3.5 _+ 3.5 
Quinidine Verapamil C 2.2 _+ 0.4 
Tamoxifen Verapamil NC * 10.8 _+ 0.3 
Trifluoperazine Verapamit C 1.0 _+ 0.5 
Trifluoperazine Mefloquine NC 
Verapamil Cyclosporin C 0.58 _+ 0.26 
Verapamil Mefloquine NC - 
Vinblastine Verapamil NC - 
* Weakly competitive--see t xt. 
1.6 
ranging from 0 to 0. l /zM. Note that in this figure (and in 
the following figure (Fig. 4), the same maximal degree of 
cytotoxin accumulation is reached whether a single re- 
verser is present or a combination of two. We feel that this 
argues for the fact that P-glycoprotein is completely 
blocked at these high levels of reversers. Previous data 
using a wide range of reversers (Lan et al., in press) 
confirms this by showing that for twenty different re- 
versers, the plateau reached at maximal reversal was ev- 
erywhere very similar. From each curve we computed the 
intrinsic K i for mefloquine acting as a reverser of P-glyco- 
protein, using Eq. A-4 of Appendix A (see Section 2). 
These K~ values are plotted against the cyclosporin A 
concentrations in Fig. 3B. The Kintrinsi  c clearly increases 
consistently with increasing cyclosporin A concentrations. 
The solid line is the regression of Kint,n~ic on [cyclosporin 
A] and has a slope equal to 29.3 (/zM) 1, and regression 
coefficient of 0.992. The computed Kintrinsi c for the effect 
of cyclosporin A on the modulation by mefloquine is, from 
the slope and intercept of this line, 28.4 nM. From the data 
for daunomycin uptake with no mefloquine present, but at 
increasing concentrations of cyclosporin A, we calculated 
(Table 2) the Kintrinsi c for the effect of cyclosporin A alone 
on P-glycoprotein. The value found was 34 nM. If meflo- 
quine and cyclosporin A compete with each other at the 
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Fig. 5. Additional examples of competitive and non-competitive interactions between modulators of P-glycoprotein. As in Fig. 4, but here studying the 
effect of verapamil as variable modulator on accumulation of daunomycin at 2 nM by P388 leukemia cells, during 1 h at 37°C, both in the presence and 
absence of (A) quinidine, (B) dipyridamole, (C) tamoxifen, (D) mefloquine. The calculated values of Kintrinsi c (see text) for verapamil -t- S.E. are plotted 
against he concentrations of the relevant fixed modulator. Each replot is derived from 7, 4, and 6 individual experiments in the case of quindine, 
dipyridamole, and tamoxifen, respectively. For mefloquine, the replot is derived from a single experiment, the S.E. values being taken directly from the 
curve-fits, as in (C). 
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increasing the Kintrinsi c for mefloquine as a modulator 
should be identical with its effect on blocking P-glyco- 
protein, increasing the amount of accumulated auno- 
mycin. This is close to what we find. We performed a
similar experiment with the P388 cells that had been 
transfected with the human MDR1 gene (the P388 VMDR 
C.04 strain). We found the same type of behaviour (not 
shown). 
Fig. 4A-C show comparable xperiments where now 
verapamil is the fixed modulator, while the concentration 
of cyclosporin (Fig. 4A) or mefloquine (Fig. 4B) was 
varied over a range of values. For both of these, the 
verapamil concentration was fixed at one of four values. 
Fig. 4C shows the plots of the computed gintr ins i  c for 
cyclosporin A (upper solid line and open circles) and 
mefloquine (lower solid line and solid circles) as a func- 
tion of verapamil concentration. In order to put all the data 
points on a single graph, we plot here the relat ive values 
of Kintrinsi c,  the value at each [verapamil] being computed 
as a ratio of the value for zero verapamil. The effect of 
verapamil on Kintrinsi c in the case of cyclosporin is a 
consistent increase in K~, while for mefloquine, no consis- 
tent increase is seen, The regression of Kintrinsi c for cy- 
closporin A on [verapamil] has a slope of 0.086 /zM) - l ,  
and a regression coefficient of 0.975. From the slope and 
intercept of this line, we calculate a Kintrinsi c of 0.58 ___ 0.26 
/zM for the effect of verapamil on increasing the Kinu.insi c 
for cyclosporin. We performed similar experiments with 
the P388 cells that had been transfected with the human 
MDR1 gene. We found the same type of behaviour (not 
shown). The effect of verapamil tself as a reverser (Table 
1) can be described by a Kintrin~i c of 0.23 + 0.04, hardly 
different from the value computed from Fig. 4A. The 
regression coefficient in the case of mefloquine and vera- 
pamil is 0.427 and has a slope of 0.123 _+ 0.192 (/zM) -~ 
(not significantly different from zero) and no meaningful 
K i can be computed. Fig. 4D and Fig. 5 depict the results 
of experiments with another 6 reverser pairs. Here we have 
plotted only the replots of the dependence of computed 
values of Kintrinsi c for each variable reverser, on the con- 
centration of the fixed reverser. Table 3 records the Kintrinsi c 
values found from the replots, where appropriate slopes are 
statistically significant. Examples of both competitive and 
non-competitive b haviour are found. 
4. Discussion 
Since P-glycoprotein has a role in clinical drug resis- 
tance, many investigators have focussed on strategies to 
inhibit the action of this protein. It is now well docu- 
mented that many drugs, including verapamil and cy- 
closporin A [12,14] are able to reverse multidrug resis- 
tance. To understand the multidrug resistance phe- 
nomenon, it is important o study the mechanism of the 
reversing effect of these agents. The problem is not easy, 
one of the reasons being that the compounds that modulate 
P-glycoprotein represent a wide range of chemical struc- 
tures and drug classes. Despite the numerous tudies per- 
formed in order to elucidate the mechanism of P-glyco- 
protein mediated drug efflux, little is understood about 
how pump inhibition is brought about [23,24]. 
Consider first the data depicted in Fig. IA. Clearly, the 
addition of verapamil brings about a marked increase in 
the accumulation of daunomycin in the resistant P388 
cells, consistent with a reversal by verapamil of P-glyco- 
protein in these cells. The kinetics of the effect of vera- 
pamil are simple. The Hill number is unity and the Kintrinsi c 
0.23 /xM. In contrast, the behaviour of vinblastine as a 
reverser is better described by a Hill number of 2 (Fig. 
I B), consistent with pairs of vinblastine molecules co-op- 
erating at the active centre of P-glycoprotein in order to 
bring about reversal of its action. As recorded in Table 1, 
we find that a number of other reversers imilarly appear 
to be co-operative in their action against P-glycoprotein. 
Although we do not know of any other study that has 
reported co-operative behaviour in the reversal of P-glyco- 
protein, there are reports [25,26] of co-operative behaviour 
of substrate molecules on P-glycoprotein. Thus, dauno- 
mycin pumping appears to display a Hill number of 2. Our 
list in Table 1 includes a well-known substrate of the 
pump, vinblastine, and also cyclosporin which evidence 
shows to be a substrate [27], as well as other molecules for 
which it is not known if they are, or are not, substrates. 
Our data add to the earlier studies that point to the 
complexity of the substrate or reverser interactions on 
P-glycoprotein. That P-glycoprotein is composed of two 
structurally similar halves [28] might provide a physical 
basis for the ability of the system to bind to pairs of 
substrate and/or reverser molecules. 
The data of Figs. 3-5 (summarised in Table 3) suggest 
that at least two classes of binding sites for reversers exist 
on the P-glycoprotein of these P388 cells. Thus with 
verapamil as variable substrate, mefloquine, tamoxifen and 
vinblastine are non-competitors or else very weakly com- 
petitive (Fig. 5C and D, and data not shown). This puts 
verapamil in one class, and puts mefloquine, tamoxifen 
and vinblastine in another. With mefloquine as variable 
substrate (Fig. 4D and Fig. 5D), both verapamil and 
trifluoperazine behave as non-competitors, confirming that 
verapamil and mefloquine are in two different classes and 
suggesting that trifluoperazine might be together with vera- 
pamil, since it is apart from mefloquine. Fig. 4D confirms 
that trifluoperazine and verapamil are in the same class, 
since they compete with each other. Fig. 5A and B suggest 
that dipyridamole and quinidine are in the verapamil/tri- 
fluoperazine class, since they compete with verapamil. 
Finally, cyclosporin seems to be able to interact with both 
sites for reversal binding since it competes with verapamil 
(Fig. 4A and C) and also with mefloquine (Fig. 3). In all 
the cases that showed clear evidence for competition, the 
Kintrinsi c measured by studying competition was not far 
different from the value of the appropriate K~ntri,~ c mea- 
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sured with the putative competitor in isolation (Table 3). 
This suggests that a competitor binds to the same site 
when it competes with other substrates as when, on its 
own, it reverses P-glycoprotein. True substrates (e.g. vin- 
blastine) and reversers which have not yet been demon- 
strated to be substrates (e.g. dipyridamole) appear in both 
classes of sites. 
How do our results compare with those of previous 
investigators? Consider first the interactions between re- 
verser and cytotoxins. Here, Periera et al. [29] have found 
that the inhibitory effect of verapamil on the P-glyco- 
protein associated efflux of the substrate THP-adriaycin in 
living cells, is non-competitive. In contrast, Naito and 
Tsuruo [30] reported a competitive inhibition by verapamil 
of ATP-dependent high affinity vincristine binding to the 
plasma membrane of MDR K562 cells. Tsuruo's group 
observed a lower potentiation of adriamycin cytotoxicity 
compared with that of vincristine by calcium channel 
blockers in drug resistant tumor cells. They suggested that 
this could indicate different mechanisms for the modula- 
tion by verapamil of adriamycin and vincristine action in 
tumor cells [31,32]. 
Spoelstra et. al. [33] reported that daunorubicin and 
verapamil are non-competing substrates for P-glycoprotein. 
Tamai and Safa [34] have shown that different substrate 
binding sites exist within P-glycoprotein, that substrates 
for these binding site are kinetically distinguishable and 
may interact non-competitively. Tamai and Safa found that 
there is competitive interaction of cyclosporin A with the 
Vinca alkaloid-binding site of P-glycoprotein in 
multidrug-resistant cells. They also reported that in iso- 
lated membrane vesicles, cyclosporin A inhibited vinblas- 
tine photo affinity labeling of P-glycoprotein in a dose 
dependent manner, and competitively inhibited the high 
affinity [3H]vincristine uptake. The data, taken together, 
suggest hat verapamil s a non-competitor f the cytotox- 
ins, while cyclosporin A is a competitor. 
Consider now the interactions between pairs of modula- 
tors. Most previous workers have used cell killing as an 
indicator of such interactions. In such cases, if the two 
modulators compete with each other, their effects can only 
be additive. If they do not compete and act at different 
sites, they will act synergistically. On this basis, Hu et al. 
[15] proposed a synergistic interaction for cyclosporin A 
and verapamil in the correction of doxorubicin resistance 
in MDR sublines of T-cell CEM/CCRF cells. However, 
when Samuels et. al. [35] analysed ata of Hu et al., using 
isobologram analyses, they found additive or even subaddi- 
rive effects, rather than synergistic interactions. In contrast, 
another group, Ossan et al. [36], who also studied the 
effects of cyclosporin A and verapamil as modulators for 
vincristine and daunomycin in T-cell acute lymphatic 
leukemia GM3639, again using isohologram analysis, 
found that the combined modulators acted synergistically 
in correcting vincristine and daunomycin resistance. Also, 
Ishida et al. [37], who studied the combined action of 
cyclosporin and verapamil on the resistance to vincristine 
of a P-glycoprotein positive MDR human tumor cell line, 
found, by isobologram analysis, that this action was 
supra-additive. Broxterman et al. [38] found that cy- 
closporin A and verapamil have different effects on energy 
metabollism in multi-drug resistant tumour cells, suggest- 
ing that their modulatory effect is mediated through two 
different modulatory sites. In contrast, Rao and Scarbor- 
ough [39], using a rather direct method which analysed the 
effect of the modulators on the ATPase activity of the 
isolated P-glycoprotein, found good evidence for a compet- 
itive interaction between cyclosporin A and verapamil. It is 
difficult to reach a consensus viewpoint here, since very 
different methodologies have been used, but the more 
direct analysis would suggest hat competition between 
these two modulators may be the better model. 
Our data and previous analyses confirm that there exist 
at least two classes of binding sites for the different 
reversers. Each binding site is itself complex, in that it can 
interact with pairs of reverser molecules imultaneously. 
Our data are, therefore, consistent also with reports of 
co-operativity in the pumping of daunomycin by the pump. 
This model is thus compatible with all the data except for 
some of the studies based on the isobologram analyses. 
As clinical studies of chemotherapy modulation are 
developed, the combination of subtoxic doses of different 
modulators having different modes of action, that allow 
synergistic effects, will be of great importance. Mefloquine 
and verapamil represent one pair of modulators that, in our 
hands, appear to be largely non-competitive and hence are 
potentially synergistic. If we can find additional members 
of these two classes, or additional such classes, we might 
be able to formulate combinations of modulators which 
will include synergistic partners. These would be more 
effective in reversing drug resistance than those that we 
have previously proposed (Lyubimov et al., in press). 
Acknowledgements 
We wish to thank Professor Avner Ramu of the Had- 
dasah-Hebrew University Medical School for the gift of 
resistant P388 leukemia cells. This work is supported by 
the Binational Science Foundation Grant #93/00135 to 
W.D.S and M.M. Gottesman, the Israel Cancer Research 
Fund, Else Koppel in Israel, and by the Stein family in the 
USA, Israel and England. 
Appendix A 
A. 1. Interpretation of apparent K i L'alues for the action of 
chemosensitisers in re~,ersing drug accumulation 
Consider a cell into which a cytotoxic drug is both 
entering and leaving by simple diffusion, while the drug is 
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also being pumped out of the cell by a membrane-bound 
pump. Let p be the permeability coefficient for this 
drug/cell  pair, and let the pump act on the drug with a 
maximum velocity of V per unit area and a Michaelis 
parameter (describing saturation of the pump) of K m. Then 
if the concentration of cytotoxin outside the cell is D e, 
while that within the cell is D i, and the cell has surface 
area A, the rate of drug influx is p X D e × A and the rate 
of drug efflux is pXDiXA+(Di 'V 'A / (D i+Km)) .  
When the internal concentration of cytotoxin is low, i.e., 
when D i is low in comparison with Kin, the effiux term 
simplifies to (p + V/K m) X D i XA. At the steady-state 
for drug accumulation, the rate of influx is equal to the rate 
of effiux and we can write: 
Di P 
De ( p + V/Km) 
1 
1 + Kin.------ fi 
1 
- - -  (A - l )  
(1 +R)  
where we write R in place of V/K  m "p, this being the 
overall factor that determines the degree of resistance of 
the cell to the cytotoxin. Eq. A-1 gives the ratio of 
cytotoxin within the cell compared to that outside the cell 
and is the relevant parameter for investigating the effect of 
pump-reversing agents on both cytotoxin accumulation and 
cell killing (Lan et al., in press). Thus, if R is zero, 
D~ = D e and the resistance is zero, while at any other value 
of R, the intracellular concentration of drug is reduced by 
the factor 1/(1 + R). 
Consider now the effect of the addition of a chemosen- 
sitiser. Let this block the drug pump according to a 
Michaelis parameter (describing its ability to saturate the 
pump) of value K~. Then, at a concentration C of this 
reverser and at a low concentration of cytotoxin, it will 
block a fraction of the pump equal to C/(C + Ki), which 
we can write as 1/(1 + C'), where C' is the 'reduced 
concentration' of the reverser, i.e., its concentration di- 
vided by its appropriate Michaelis parameter. Now, this 
chemosensitiser can in principle block the cytotoxin's ef- 
flux either competitively or non-competitively. For both 
modes of inhibition, however, the effect of pump inhibi- 
tion on cytotoxin efflux at low cytotoxin concentrations as 
compared with the cytotoxin's Kin, is tO reduce the value 
of V/K  m in Eq. A-1 by the factor 1/(1 + C'). This 
follows since for competitive inhibition K m is multiplied 
by (1 + C'), while for non-competitive inhibition V is 
divided by this same term. We can therefore write: 
D~ 1 
De 1 + (1 + C') 
(1 +c') 
- (1 +R+C' )  (A-2)  
The internal cytotoxin concentration at zero concentration 
of reverser (which we define as D 0) is given by setting C' 
equal to zero in Eq. A-2, whence we have: Do/D e = 1/(1 
+ R), while the cytotoxin concentration ratio at infinite 
concentration of reverser, D~/D e, is equal to unity. (Put 
C '= co in Eq. A-2.) 
For cytotoxin accumulation, if we write D o for the 
amount of accumulation at zero concentration of reverser, 
and D~ for the amount of accumulation at an infinite 
concentration of reverser, it will be obvious that D~ = D e, 
while D o = De/( l  + R). We can write the right-hand side 
of Eq. A-2 in terms of partial fractions, and substitute for 
the terms in D as follows: 
V i (1 ÷ C ' ) ( l  +g)  
D e ( I+R+C' ) ( I+R)  
1 +R+C'+R.C '  
(1 ÷R) (1  +R+C' )  
1 R C' 
I+R I+R ' I+R+C'  
Hence, 
D i = D O + ( D~ - Do). 
C 
1 +R+ C' 
C 
= D O + ( D~ - Do). (A-3) 
(1 ÷R)K i÷C 
This gives an expression for how the accumulation of 
cytotoxin depends on C', in terms of the accumulation at 
zero reverser and at a maximal concentration of reverser. 
The term D~ - D o is the increment in accumulation as the 
reverser concentration is raised from 0 to infinity. 
The expression on the extreme right-hand side of Eq. 
A-3 is again a Michaelis form, but the dependence of D~ 
on the concentration of reverser C does not give directly 
the value of the intrinsic K i for the reverser, but rather 
(1 + R) times Kj. We can cast Eq. A-4 into a form that is 
independent of R and contains only experimentally deriv- 
able parameters by substituting for (1 + R) in Eq. A-3, the 
equivalent term Do/D~, obtaining: 
C 
O i =O o + (O~ -Do) .  (A-4) 
g i.(Dzc/D0) ÷ C 
from which D 0, D~, and K i can be found from the 
amount of accumulation D~ as a function of C. Note that 
this equation has been derived in terms everywhere of the 
free concentration of cytotoxin. It is, however, valid also 
for situations in which only a knowledge of the total 
concentration is known, as we proceed to show: assume 
that there is an equilibrium between free cytotoxin and 
bound cytotoxin so that Free/Bound = Y. Now rewrite Eq. 
A-4, which is in terms of Free cytotoxin, in terms of 
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Bound cytotoxin by using the substitution Free = Bound × 
Y. Then the term Y cancels out in the rewritten Eq. A-4, 
which now becomes an equation in Bound cytotoxin. Thus 
the equality is preserved and there is no need to specify 
whether it is data for free or for bound cytotoxin that is 
being analysed. Clearly, this analysis holds only if the 
concentration of cytotoxin is well below that required to 
saturate the sites to which it is bound. At the very low 
(nmolar) concentrations of cytotoxin that we use in the 
present paper, this condition is satisfied. We have unpub- 
lished results which suggest hat saturation of intracellular 
cytotoxin-binding begins to occur above concentrations of
a few micromolar of vinblastine and of daunomycin. 
A.2. Competitive and non-competitive interaction between 
reversers 
We shall treat competitive and non-competitive interac- 
tion between two reversers, C and B. Competitors can 
block the pump, but only one or the other can bind at any 
one time. At low cytotoxin concentrations, the forms that 
will be found will be E, EC, and EB only. We define the 
term Tote (see Stein ([40])) as equal to E + EC + EB 
which can be expressed, therefore, as E (1 + C' + B'). For 
non-competitors, the additional form ECB is found, since 
both C and B can bind simultaneously, soTotE is equal to 
E + EC + EB + ECB and can be expressed as E(1 + C')(1 
+ B'). We take the Eq. A-1 for reversal derived above and 
divide the term R by the appropriate factor (1 + C' + B') 
or (1 + C')(I + B'), getting for 
Competition: 
D i (1 ÷C'÷B' )  
- -  = (A -5)  
D e ( I+R+C'+B' )  
Non-competition: 
(1 +c ' )  
- ( R (A -6)  
De \ 1 +C'+ (1 ÷B'~ 
We take now the case of the effect of such second 
reversers on cytotoxin accumulation. From Eq. A-5 above, 
where the second reverser is competitive, the value of 
Do/D e is now equal to (1 + B ' ) / ( I  + R + B'). We use this 
value in the expansion of Eq. A-5 above as follows: 
D i ( I+C '+B' ) ( I+R+B' )  
D e (1 +R+C'+B' ) (1  +R+B' )  
1 + B' R.C' 
= + 
1 +R+B'  ( l  +R+B' ) ( I  +R+C'+B' )  
C' 
=D 0+(D~-D0) . I+R+C,+B,  
C 
=D O + (D~ -Do) .  Ki(1 +R +B' )  + C 
C 
= D O + ( D~: - Do). De (A-7) 
Ki-~o(l +B')  +C 
Thus the computed value of the intrinsic K i, obtained 
by using Eq. A-3 directly for the first reverser, is increased 
by the factor (1 + B'), in the presence of concentration B' 
of the second reverser. The case of a non-competitive 
second reverser is readily handled. From Eq. A-6 above, 
Do/D e has the value (1 + B ' ) / ( I  + R + B'). Using this 
value in Eq. A-3, and using the correct value of D 0, while 
we replace R in this equation by R/(1 + B'), as in Eq. A-6 
above, we obtain: 
D i = D O + (D~ - D o) • 





= D° + ( D~ - D°)" D~ (A-8) 
K i - -+C 
Do 
It will be seen that the effect of a second non-competitive 
reverser on cytotoxin accumulation is, therefore, to leave 
the computed value of the intrinsic K~ unchanged. 
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